Nayak Sanjay 4

What Happened

• Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 10,348 shares of common stock on 2026-02-12. The weighted-average sale price was $9.04 per share, resulting in proceeds of approximately $93,546.
• This sale was not a discretionary trade: it was executed under a durable automatic sale instruction to effect a sell-to-cover election to satisfy tax withholding obligations related to restricted stock units that vested on 2026-02-11.

Key Details

• Transaction date: February 12, 2026.
• Price: Weighted average $9.04; individual trades ranged from $8.9950 to $9.0873 (report notes multiple transactions; reporting person can provide per-trade breakdown on request).
• Shares sold: 10,348; proceeds ≈ $93,546.
• Reason/footnote: Sell-to-cover for tax withholding tied to RSU vesting; sale executed under an automatic instruction adopted Feb 21, 2024 (not a discretionary sale).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timing: Form 4 filed 2026-02-17 for a 2026-02-12 transaction — filed after the typical 2-business-day reporting window for Form 4.

Context

• This was a tax-withholding sale (sell-to-cover) related to RSU vesting, which is generally routine and does not necessarily indicate insider sentiment about the company. Purchases typically carry more informational weight for investors than routine sales for tax purposes.